RecruitingAdverse Pregnancy OutcomesAtopic Dermatitis
An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis (AD)
Eligible age
18–49 yrs
Accepts
Women
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The objective of this study is to describe and compare the incidence of adverse pregnancy outcomes (spontaneous abortion/miscarriage, stillbirth) and prevalence of adverse infant outcomes (major congenital malformations \[MCMs\], small for gestational age \[SGA\]) in women with AD who are treated with dupilumab during pregnancy relative to women with AD who are not treated with dupilumab during pregnancy.
Sponsor: Regeneron Pharmaceuticals
Where it's recruiting
Massachusetts
Boston
Source: ClinicalTrials.gov · NCT03936335 · last updated 2025-08-03